Clinical Grade RetroNectin® Reagent Available To Support Gene Therapy Clinical Research

Clinical Grade RetroNectin® Reagent Available To Support Gene Therapy Clinical
                                   Research

PR Newswire

MOUNTAIN VIEW, Calif., June 17, 2013

MOUNTAIN VIEW, Calif., June 17, 2013 /PRNewswire/ --In an effort to aid
progress in gene therapy clinical research, representatives of Clontech
laboratories, Inc. and its parent company Takara Bio Inc. announce the
availability of clinical grade RetroNectin® reagent for direct supply to
biomedical researchers.

RetroNectin® reagent is designed to enable efficient retroviral transduction
of genes into hematopoietic stem cells as well as lymphocytes and other blood
cells. The RetroNectin® method has been recognized as a standard gene
transduction method in ex vivo gene therapy around the world. In addition,
RetroNectin® reagent has another remarkable feature that can also be useful
for cell therapies: during the expansion culture of human T lymphocytes,
RetroNectin® reagent helps to increase proportion of naïve T cells. This
RetroNectin® induced T cell method has already become available as a cancer
therapy in three Japanese clinics under technical support from Takara Bio.

Takara Bio is the exclusive supplier of RetroNectin® reagent, a recombinant
human fibronectin fragment developed in 1995 by Takara Bio in collaboration
with Indiana University. It has been used in 68 gene therapy clinical trials
in 44 institutes and hospitals in 10 countries to date.

Previously, access to clinical-grade RetroNectin® reagent required a Material
Transfer Agreement (MTA) between a research institution and Takara Bio.
Researchers may now submit direct orders to Clontech or local Takara Bio
subsidiaries for RetroNectin® (GMP), which is manufactured as a
quality-assured product according to guidelines for Good Manufacturing
Practice (GMP). The Drug Master File for RetroNectin® (GMP) has been filed
with the U.S. Food and Drug Administration. In a recent study published in
Science Translational Medicine  in March 2013, scientists at Memorial
Sloan-Kettering Cancer Center reported an immunotherapy strategy for the
treatment of five adult patients with acute lymphoblastic leukemia. Each
patient's T cells were extracted, altered by introduction of DNA that would
cause the cells to attack tumor cells, and infused back into the patient's
bloodstream. According to researchers, all patients achieved tumor eradication
and complete remission. RetroNectin® reagent was used during T cell
transduction.

Corresponding author Dr. Renier J. Brentjens said, "It was very clear to us
even 10 years ago that the use of RetroNectin® coated plates markedly,
massively improved gene transfer." Dr. Brentjens continued, "The methodologies
that many of us now use have been developed over a number of years. Once you
have a system that works, you become very reliant and dependent on those
reagents."

"RetroNectin® reagent has become a standard reagent for many gene transfer
protocols worldwide," said Carol Lou, General Manager of Clontech. "We are
sure that such direct access to RetroNectin® (GMP) without MTA execution will
make this reagent available much more easily to any scientists or clinicians
interested in RetroNectin® clinical applications, which aligns with Takara
Bio's mission of contributing to the health of mankind through gene therapy."

About Clontech Laboratories, Inc.
Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc.,
develops, manufactures, and distributes a wide range of life science research
reagents under the Clontech and Takara brands. Key products include the Living
Colors fluorescent proteins; high-performance qPCR and PCR reagents (including
theTaKaRa Ex Taq^®,TaKaRa LA Taq^®, Titanium^®, and Advantage^® enzymes); RT
enzymes and SMART^™ library construction kits; the innovative In-Fusion^®
cloning system; Tet-based inducible gene expression systems; and a range of
Macherey-Nagel nucleic acid purification tools. These and other products
support applications including gene discovery, regulation, and function;
protein expression and purification; RNAi and stem cell studies; and plant and
food research. For more information, visit www.clontech.com.

About Takara Bio Inc.
Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan.
As a world leader in biotechnology research and development, Takara Bio was
the first company to market PCR technology in Japan and is also the developer
of the RetroNectin^® reagent, which is used as a world-standard in gene
therapy protocols. In addition to providing research reagents and equipment to
the life science research market, Takara Bio has active research and product
development activities in the fields of gene and cell-based therapy, and
agricultural biotechnology; and is committed to preventing disease and
improving the quality of life for all people through the use of biotechnology.
Through strategic alliances with other industry leaders, the Company aims to
extend its reach around the world. More information is available
athttp://www.takara-bio.com.

For more information, contact:

Lorna Neilson, Ph.D.
Director, Business Development
Clontech Laboratories, Inc.
A TakaraBio Company
lorna_neilson@clontech.com
(650) 919-7372

SOURCE Clontech Laboratories, Inc.; Takara Bio Inc.

Website: http://www.clontech.com
Website: http://www.takara-bio.com